Marvel Biosciences Corp (MRVL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marvel Biosciences Corp (MRVL) has a cash flow conversion efficiency ratio of 0.049x as of October 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-178.46K ≈ $-129.09K USD) by net assets (CA$-3.65 Million ≈ $-2.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MRVL equity financing ratio to measure how much of total assets are equity-financed.
Marvel Biosciences Corp - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Marvel Biosciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Marvel Biosciences Corp (MRVL) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Marvel Biosciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marvel Biosciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GIGLIO.COM S.P.A. O.N.
F:5JR0
|
N/A |
|
Ecoslops SA
PA:ALESA
|
0.259x |
|
HLT Global Bhd
KLSE:0188
|
-0.159x |
|
Digistar Corporation Bhd
KLSE:0029
|
-0.152x |
|
Rossi Residencial S.A
SA:RSID3
|
-0.033x |
|
Altheora SA
PA:ALORA
|
0.089x |
|
Viet Phat Import Export Trading Investment JSC
VN:VPG
|
N/A |
|
Pantera Lithium Ltd
AU:PFE
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Marvel Biosciences Corp (2020–2025)
The table below shows the annual cash flow conversion efficiency of Marvel Biosciences Corp from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see Marvel Biosciences Corp market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | CA$-4.01 Million ≈ $-2.90 Million |
CA$-1.15 Million ≈ $-832.13K |
0.287x | -31.21% |
| 2024-07-31 | CA$-2.83 Million ≈ $-2.04 Million |
CA$-1.18 Million ≈ $-853.23K |
0.417x | -46.11% |
| 2023-07-31 | CA$-1.72 Million ≈ $-1.24 Million |
CA$-1.33 Million ≈ $-963.72K |
0.775x | +106.90% |
| 2022-07-31 | CA$195.54K ≈ $141.45K |
CA$-2.19 Million ≈ $-1.59 Million |
-11.220x | -1828.46% |
| 2021-07-31 | CA$2.36 Million ≈ $1.70 Million |
CA$-1.37 Million ≈ $-991.45K |
-0.582x | +87.16% |
| 2020-07-31 | CA$118.80K ≈ $85.94K |
CA$-538.53K ≈ $-389.57K |
-4.533x | -- |
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hal… Read more